Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher rates of remission compared with calorie restriction alone, finds a trial published by The BMJ today.
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Biotech Investments
Issuer: Immunic AG / Key word(s): Quarter Results/Half Year Results 08.08.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement.